AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28382785 — intervention group
Group type: COMPARATOR
Intervention: Readymade growth factors
Number of subjects: 20
Study 26811165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 24
Study 26811165 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 24
Study 25139609 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGM)
Number of subjects: 87
Study 25139609 — intervention group
Group type: COMPARATOR
Intervention: Frequent point-of-care (POC) measurement
Number of subjects: 87
Study 22495074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 402
Study 19384120 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical lidocaine
Number of subjects: 132
Study 19384120 — intervention group
Group type: COMPARATOR
Intervention: Intracervical lidocaine
Number of subjects: 132
Study 17240221 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (EC)
Number of subjects: 1950
Study 17240221 — intervention group
Group type: COMPARATOR
Intervention: Direct pharmacy access to emergency contraception (EC)
Number of subjects: 1950
Study 17240221 — intervention group
Group type: COMPARATOR
Intervention: Clinic access to emergency contraception (EC)
Number of subjects: 1950
Study 15695981 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Number of subjects: 50
Study 15695981 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate
Number of subjects: 50
Study 12148711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy services
Number of subjects: 23
Study 9808807 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-Matched Materials
Number of subjects: 1864
Study 9808807 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Materials
Number of subjects: 1864
Study 9808807 — intervention group
Group type: COMPARATOR
Intervention: No Educational Materials
Number of subjects: 1864
Study 8704420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Kangkui Decoction (BSKKD)
Number of subjects: 150
Study 8704420 — intervention group
Group type: COMPARATOR
Intervention: Injectio cimetidine
Number of subjects: 150
Study 30489324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative compliance surveillance and prompting strategy directed toward the care team
Number of subjects: 100
Study 30489324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 29075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatuff™ knee-length socks containing Kevlar fibres worn for 16 weeks
Number of subjects: 90
Study 29075507 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 29075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sock wearing
Number of subjects: 90
Study 29075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by EQ5D5L
Number of subjects: 90
Study 25261090 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SMT)
Number of subjects: 56
Study 25261090 — intervention group
Group type: COMPARATOR
Intervention: Sham spinal manipulation (sham-SMT)
Number of subjects: 56
Study 23325373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 0
Study 23325373 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 23325373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22021700 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (2 ml intravenously)
Number of subjects: 6
Study 22021700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml of 0.9% NaCl intravenously)
Number of subjects: 6
Study 19692881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g) administered after intubation before surgery
Number of subjects: 40
Study 19692881 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mL 0.9% NaCl infused intravenously)
Number of subjects: 40
Study 16478839 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Prior scheduled appointment
Number of subjects: 384
Study 16478839 — intervention group
Group type: COMPARATOR
Intervention: Group A: Usual discharge care
Number of subjects: 384
Study 16478839 — intervention group
Group type: COMPARATOR
Intervention: Group B: Free prednisone and transport vouchers with telephone reminder
Number of subjects: 384
Study 16478839 — intervention group
Group type: COMPARATOR
Intervention: Group A, B, C
Number of subjects: 384
Study 14964347 — intervention group
Group type: EXPERIMENTAL
Intervention: Master Amino Acid Pattern (MAP®) as a sole and total substitute of dietary proteins
Number of subjects: 500
Study 14964347 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP in conjunction with ANC/OMP
Number of subjects: 500
Study 11103054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa high-dose (40,000 U)
Number of subjects: 201
Study 11103054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa low-dose (20,000 U)
Number of subjects: 201
Study 11103054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 9263612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Number of subjects: 453
Study 9263612 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 1 g oral calcium daily
Number of subjects: 453
Study 8518909 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of the superior rectal artery
Number of subjects: 24
Study 8518909 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete rectal mobilization to the pelvic floor
Number of subjects: 24
Study 8518909 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of anastomosis (both techniques)
Number of subjects: 24
Study 3440813 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 30 min
Number of subjects: 20
Study 3440813 — intervention group
Group type: COMPARATOR
Intervention: Rest for 30 min
Number of subjects: 20
Study 28704254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 178
Study 28704254 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 178
Study 27125531 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 155
Study 27125531 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 155
Study 27125531 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study 24525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg/d) + Citalopram (20 to 60 mg/d)
Number of subjects: 40
Study 24525635 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 to 60 mg/d) + Placebo
Number of subjects: 40
Study 23298508 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens 320 mg every day for 24 months
Number of subjects: 100
Study 23298508 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 1 mg every day for 24 months
Number of subjects: 100
Study 20399899 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (CS) 800 mg daily for 3 months
Number of subjects: 129
Study 19478343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea extract, 100 mg twice daily for 4 weeks
Number of subjects: 22
Study 19478343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea extract
Number of subjects: 22
Study 19478343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15904630 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat 80 mg/day
Number of subjects: 348
Study 15904630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 12683707 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary pulmonary rehabilitation program (walking, breathing exercises, postural drainage, controlled coughing, lifestyle changes) for 30 minutes twice daily for four weeks
Number of subjects: 40
Study 12683707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 10613426 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 days, 20 g x d(‐1))
Number of subjects: 10
Study 7557824 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (CBS) 240 mg bid for 4-8 weeks, followed by placebo maintenance treatment
Number of subjects: 53
Study 7557824 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing
Number of subjects: 53
Study 7557824 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (CBS)
Number of subjects: 53
Study 7557824 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 53
Study 1940120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0
Study 6266576 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-421 20 mg
Number of subjects: 9
Study 6266576 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-421 5 mg
Number of subjects: 9
Study 6266576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30793860 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone adhesive dressings with standard preventive care
Number of subjects: 71
Study 30793860 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preventive care only)
Number of subjects: 71
Study 30080086 — intervention group
Group type: EXPERIMENTAL
Intervention: SOSA support group
Number of subjects: 92
Study 27776081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 10
Study 27776081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24582842 — intervention group
Group type: EXPERIMENTAL
Intervention: Free wrist motion
Number of subjects: 10
Study 24582842 — intervention group
Group type: COMPARATOR
Intervention: Splinted wrist motion (blocking radial and ulnar deviation)
Number of subjects: 10
Study 22985672 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral DHEA for four weeks
Number of subjects: 0
Study 22985672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22985672 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study 20179296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3600
Study 20179296 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3600
Study 20179296 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 3600
Study 16930802 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Theanine at the start of the experimental procedure
Number of subjects: 12
Study 16930802 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Theanine midway through the experimental procedure
Number of subjects: 12
Study 16930802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16930802 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 12
Study 16421692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual defibrillator (group A)
Number of subjects: 63
Study 16421692 — intervention group
Group type: COMPARATOR
Intervention: Standard DDD pacing (group B)
Number of subjects: 63
Study 11879259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (dose range 25‐100 mg)
Number of subjects: 2077
Study 10999086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 7.5 mg/kg
Number of subjects: 58
Study 10999086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 10 mg/kg
Number of subjects: 58
Study 7474755 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side anastomoses (Group A, 60 patients)
Number of subjects: 150
Study 7474755 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomoses (Group B, 40 patients)
Number of subjects: 150
Study 7474755 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end and end-to-side anastomoses (Group C, 50 patients)
Number of subjects: 150
Study 7474755 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group O, 30 patients)
Number of subjects: 150
Study 2174575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast medium (OBCM)
Number of subjects: 40
Study 6943331 — intervention group
Group type: COMPARATOR
Intervention: Extracoronal wire ligation (Group I)
Number of subjects: 18
Study 6943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite restorative material (Group II)
Number of subjects: 18
Study 6943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and II)
Number of subjects: 18
Study 28488825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (2 sessions per week, 45-60 minutes each for 12 weeks)
Number of subjects: 36
Study 28488825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 28488825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 36
Study 27212617 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein formula (n=550)
Number of subjects: 1678
Study 27212617 — intervention group
Group type: COMPARATOR
Intervention: Lower protein formula (n=540)
Number of subjects: 1678
Study 27212617 — intervention group
Group type: COMPARATOR
Intervention: Observational group (exclusively breastfed for at least three months, n=588)
Number of subjects: 1678
Study 24693973 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oxidation protein products (AOPP) levels measured at 2.5, 5.5, 10.5, 15 and 24 months of age.
Number of subjects: 312
Study 24693973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster membership based on AOPP levels (Group A: lower AOPP levels, Group B: higher AOPP levels).
Number of subjects: 312
Study 24693973 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms GCLC RS10948751 and HMOX1 RS17885925.
Number of subjects: 312
Study 23229858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilobradine 0.25-5 mg doses
Number of subjects: 0
Study 23229858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19902278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraseptal anaesthesia (ISA)
Number of subjects: 35
Study 19902278 — intervention group
Group type: COMPARATOR
Intervention: Periodontal ligament anaesthesia (PLA)
Number of subjects: 35
Study 18763638 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape procyanidins (GPC) 100 mg/day for 60 days
Number of subjects: 60
Study 18763638 — intervention group
Group type: COMPARATOR
Intervention: Starch capsule (control)
Number of subjects: 60
Study 17182445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine pharmacotherapy
Number of subjects: 402
Study 12819312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-modification program (goals: at least 7% weight loss and at least 150 min of physical activity per week)
Number of subjects: 3234
Study 12819312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234
Study 12819312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 10874895 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous r-hirudin (25 mg twice daily)
Number of subjects: 19
Study 9378876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (experimental group)
Number of subjects: 0
Study 9378876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 1551969 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day prednisolone
Number of subjects: 20
Study 1551969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3925176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubing changes every 2 days (Group A)
Number of subjects: 52
Study 3925176 — intervention group
Group type: COMPARATOR
Intervention: Tubing changes every 4 days (Group B)
Number of subjects: 52
Study 3925176 — intervention group
Group type: COMPARATOR
Intervention: Historic series (comparison)
Number of subjects: 52
Study 30366601 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 30366601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 29448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-edge swap (degree-preserving randomization of the configuration model)
Number of subjects: 0
Study 29448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Single edge replacement (full randomization of the Erdős‐Rényi random graph)
Number of subjects: 0
Study 27741192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-fetal digoxin (1.0 mg)
Number of subjects: 270
Study 27741192 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic digoxin (1.0 mg)
Number of subjects: 270
Study 27741192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 270
Study 24549168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme including supervised exercise sessions and information sessions
Number of subjects: 78
Study 24549168 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 78
Study 23027880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 23027880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23027880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline EDSS scores
Number of subjects: 0
Study 20403733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral water immersion (TWI)
Number of subjects: 12
Study 20403733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 12
Study 20403733 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 18686816 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment for knee OA
Number of subjects: 0
Study 18686816 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic techniques in special subgroups (acute pain exacerbation, mechanical block, early OA)
Number of subjects: 0
Study 16025963 — intervention group
Group type: EXPERIMENTAL
Intervention: Kebimin decoction (KD)
Number of subjects: 60
Study 16025963 — intervention group
Group type: COMPARATOR
Intervention: Xinfang rhinitis capsule (Control)
Number of subjects: 60
Study 14606735 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counselling intervention (stroke information package and three visits from a social worker trained in family counselling)
Number of subjects: 62
Study 14606735 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counselling intervention
Number of subjects: 62
Study 14606735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study 10591669 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.4 mg/d (group 1)
Number of subjects: 60
Study 10591669 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 0.4 mg/d (group 2)
Number of subjects: 60
Study 10591669 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 0.0 mg/d (group 3)
Number of subjects: 60
Study 8672762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 MU/day natural interferon‐α (IFNα) for 38 weeks
Number of subjects: 57
Study 1987744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (IFN-alpha-N1) combined with cyclophosphamide, doxorubicin, and cisplatin (CAP regimen)
Number of subjects: 14
Study 1987744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (IFN-alpha-N1)
Number of subjects: 14
Study 1987744 — intervention group
Group type: COMPARATOR
Intervention: Multiagent chemotherapy regimen of CAP
Number of subjects: 14
Study 6398833 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 0
Study 6398833 — intervention group
Group type: COMPARATOR
Intervention: Oxamniquine (15 mg/kg)
Number of subjects: 0
Study 31752815 — intervention group
Group type: EXPERIMENTAL
Intervention: en_línea
Number of subjects: 305
Study 31752815 — intervention group
Group type: EXPERIMENTAL
Intervention: standard group therapy
Number of subjects: 305
Study 31752815 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 305
Study 30183582 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen during surgery
Number of subjects: 1386
Study 30183582 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen during surgery
Number of subjects: 1386
Study 30183582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 1386
Study 30183582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 1386
Study 30183582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypothermia and emergency surgery
Number of subjects: 1386
Study 26926320 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 204
Study 26926320 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting guidelines for all health behaviors
Number of subjects: 204
Study 26926320 — intervention group
Group type: COMPARATOR
Intervention: Baseline health behaviors
Number of subjects: 204
Study 23317480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated VF (VF plus cognitive preparation and cognitive review)
Number of subjects: 68
Study 23317480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard VF (VF plus cognitive preparation)
Number of subjects: 68
Study 23317480 — intervention group
Group type: COMPARATOR
Intervention: No VF (exposure alone)
Number of subjects: 68
Study 23317480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated VF
Number of subjects: 68
Study 23317480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard VF
Number of subjects: 68
Study 23031172 — intervention group
Group type: EXPERIMENTAL
Intervention: FES‐assisted walking
Number of subjects: 34
Study 23031172 — intervention group
Group type: COMPARATOR
Intervention: Aerobic and resistance training (control)
Number of subjects: 34
Study 19733449 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 67